GSK to sell its Verona research operations to Aptuit
This article was originally published in Scrip
Executive Summary
In a deal that will save around 500 jobs at a facility made surplus to requirements by cuts in R&D, GlaxoSmithKline has finalised an agreement to sell the operations of its Medicines Research Centre in Verona, Italy, to the US-based drug development company Aptuit.